CRC Research Update — September 14, 2026
Today's colorectal cancer research highlights
Archive
A collection of 699 issues
Latest
Pooled Analysis Examines Prognostic Value of KRAS Mutations and Liver Metastases
Skip to content
The CRC Digest
Pooled Analysis Examines Prognostic Value of KRAS Mutations and Liver Metastases
A pooled analysis of third-line placebo-controlled trials from the ARCAD CRC Database evaluated the prognostic impact of liver metastases and KRAS mutations in metastatic colorectal cancer patients. (Clinical Colorectal Cancer)
This content is
Scoping Review Maps Global Variation in Early-Onset CRC Patterns
Skip to content
The CRC Digest
Scoping Review Maps Global Variation in Early-Onset CRC Patterns
A scoping review of studies published 2019–2024 synthesized contemporary evidence on epidemiologic, molecular, and survival differences in early-onset colorectal cancer across regions and racial/ethnic groups. (Journal of Gastrointestinal Cancer)
This content is informational
Peer-Led Campus Program Targets CRC Awareness Among Young Adults
Skip to content
The CRC Digest
Peer-Led Campus Program Targets CRC Awareness Among Young Adults
GRACCE, a community-led ambassador-driven education program, recruited student ambassadors from five universities to deliver campus-based CRC education, addressing rising incidence among young adults. (Journal of Cancer Education)
This content is informational only and does not
Vietnamese CRC Survivors Report Significant Unmet Supportive Care Needs
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Vietnamese CRC Survivors Report Significant Unmet Supportive Care Needs
A cross-sectional study of 354 colorectal cancer survivors in Vietnam identified unmet supportive care needs following primary treatment, highlighting gaps in the healthcare system and cultural context. (European Journal of Oncology Nursing)
Seven-Year Study Maps Dysplasia Patterns in Sessile Serrated Lesions
Skip to content
The CRC Digest
▪ SCREENING
Seven-Year Study Maps Dysplasia Patterns in Sessile Serrated Lesions
A retrospective analysis of all sessile serrated lesions from a single high-detection-rate endoscopist in Australia assessed the prevalence and anatomical distribution of dysplasia, a critical stage in progression to colorectal cancer. (Gastroenterology and Hepatology
Urinary Metabolomics May Improve Survival Prediction Beyond Tumor Stage
Skip to content
The CRC Digest
◇ RESEARCH
Urinary Metabolomics May Improve Survival Prediction Beyond Tumor Stage
Pre-surgery urinary metabolomic profiles improved overall survival prediction performance compared with stage- and age-based models in 76 stage I-IV CRC patients from the ColoCare Study. (Metabolomics)
This content is informational only and does not
Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic CRC
Skip to content
The CRC Digest
◇ RESEARCH
Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic CRC
A matching-adjusted indirect comparison evaluated sotorasib combined with panitumumab versus trifluridine/tipiracil plus bevacizumab in chemorefractory metastatic colorectal cancer. (Clinical Colorectal Cancer)
This content is informational only
CRC Research Update — September 13, 2026
Today's colorectal cancer research highlights
Secondary actionable fusions in MLH1-deficient MSI-H tumors may impact pembrolizumab outcomes
Skip to content
The CRC Digest
Secondary actionable fusions in MLH1-deficient MSI-H tumors may impact pembrolizumab outcomes
A molecular subanalysis of the GAstrointestinal INestable cohort evaluated secondary fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab, finding that these fusions may be enriched in MLH1-deficient colorectal cancer with mitogen-activated
Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic disease
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic disease
A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial examined quality of life in patients with RAS wild-type metastatic colorectal cancer
Real-world study of 549 Spanish patients evaluates trifluridine/tipiracil plus bevacizumab
Skip to content
The CRC Digest
▸ TREATMENT
Real-world study of 549 Spanish patients evaluates trifluridine/tipiracil plus bevacizumab
A multicenter study across 19 Spanish hospitals evaluated real-world effectiveness and safety of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer after at least two prior treatment regimens. (ESMO Gastrointestinal
FDA delays decision on zanzalintinib plus Tecentriq for metastatic colorectal cancer until March 2027
Skip to content
The CRC Digest
● REGULATORY
FDA delays decision on zanzalintinib plus Tecentriq for metastatic colorectal cancer until March 2027
The FDA has extended its approval decision for Exelixis' oral kinase inhibitor zanzalintinib in combination with Roche's Tecentriq to March 2027 while awaiting updated safety and
CRC Research Finding
Skip to content
The CRC Digest
● REGULATORY
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
© 2026 The CRC Digest —
crcdigest.com
CRC Research Update — September 12, 2026
Today's colorectal cancer research highlights
PD-L1 blockade shows activity in MSS rectal cancer when combined with radiation and chemotherapy
Skip to content
The CRC Digest
▸ TREATMENT
PD-L1 blockade shows activity in MSS rectal cancer when combined with radiation and chemotherapy
The PRECAM-R trial demonstrated that short-course radiotherapy may create an immune-priming window in microsatellite-stable tumors, allowing PD-L1 blockade to achieve a 44.8% pathologic complete response rate. (The ASCO
39-year-old proband with Lynch syndrome shows discordant tumor testing
Skip to content
The CRC Digest
◇ RESEARCH
39-year-old proband with Lynch syndrome shows discordant tumor testing
A 39-year-old man with colorectal cancer and family history fulfilling Amsterdam criteria carried the germline MLH1 c.931A>G variant, with tumors showing MSI-H status despite retained MMR protein expression. (Clinical Case Reports)
Lynch syndrome family shows MSI-H tumors despite preserved MMR protein staining
Skip to content
The CRC Digest
◇ RESEARCH
Lynch syndrome family shows MSI-H tumors despite preserved MMR protein staining
A family carrying germline MLH1 c.931A>G presented with colorectal tumors showing retained mismatch repair protein expression by immunohistochemistry but microsatellite instability-high status on sequencing, highlighting that preserved staining does
Study evaluates follow-up after positive stool-based screening in rural populations
Skip to content
The CRC Digest
▪ SCREENING
Study evaluates follow-up after positive stool-based screening in rural populations
(The American Surgeon)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
© 2026 The CRC Digest —
crcdigest.com
Collision tumor case reveals dual primary colorectal cancers with distinct molecular profiles
Skip to content
The CRC Digest
◇ RESEARCH
Collision tumor case reveals dual primary colorectal cancers with distinct molecular profiles
Researchers report a rare collision tumor composed of two adjacent primary colorectal carcinomas, one harboring a TPR::NTRK fusion with MSI-H and high tumor mutational burden, the other showing conventional adenocarcinoma